(Q37829757)

24 August 2017

1 reference

title

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors (English)

1 reference

24 August 2017

4

Axel Hauschild

1 reference

24 August 2017

Yevgeniy Balagula

1

1 reference

24 August 2017

Claus Garbe

2

1 reference

24 August 2017

Patricia L Myskowski

3

1 reference

24 August 2017

Bernardo L Rapoport

5

1 reference

24 August 2017

Christine B Boers-Doets

6

1 reference

24 August 2017

Mario E Lacouture

7

1 reference

24 August 2017

publication date

1 February 2011

1 reference

International Journal of Dermatology

24 August 2017

published in

1 reference

24 August 2017

volume

50

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

129-146

1 reference

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human Skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal Appendages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Getting under the skin of epidermal morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Skin toxicities associated with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Analysis of dermatologic events in patients with cancer treated with lapatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Mechanisms of cutaneous toxicities to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Patient-reported outcomes and the evolution of adverse event reporting in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Skin toxicities of targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Erlotinib-associated trichomegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Ocular toxicities of epidermal growth factor receptor inhibitors and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

FDA drug approval summary: panitumumab (Vectibix).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Nail toxicity associated with epidermal growth factor receptor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2010.04791.X

10.1111/J.1365-4632.2010.04791.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference